Navigation Links
Angioslide Announces First Successful Below-The-Knee Procedures in the US
Date:7/11/2012

CAESAREA, Israel, July 11, 2012 /PRNewswire/ --

Angioslide Ltd., a provider of Embolic Capture Angioplasty solutions, today announced the successful deployment of a 3X100mm PROTEUS device for treating Peripheral Artery Disease in below-the-knee (BTK) vasculature at Community Hospital in Munster, IN. Accommodating a 0.014" guide-wire, the new device allows physician to perform a PTA revascularization in BTK vessels while capturing and removing embolic particles.

"With PROTEUS having been successfully used to treat lesions in the SFA (superficial femoral artery), I had the opportunity to deploy the device in BTK procedures," said Dr. Prakash Makam of Community Hospital (Munster, IN). "It is an effective, easy to use tool that provides an alternative for removal of embolic material, including micro particles, that could compromise downstream vasculature flow and perfusion to the foot. This is especially important when treating high-risk, diabetic and critical limb ischemia (CLI) patients."

Angioslide's proprietary technology combines the functionality of a balloon angioplasty device with the addition of capture and removal of particles released during intervention.  Capture of embolic material is enabled by the inward folding of the balloon through a dedicated handle, which creates a suction effect that pulls embolic material into the cavity. When retrieved through the sheath, PROTEUS removes the captured material from the body.

"We are excited to provide a solution for capture and removal of embolic debris for below-the-knee intervention, where the clinical consequences of emboli are amplified by small vessel diameter," said Lihu Avitov, CEO, Angioslide. "The Current set of tools available on the market for BTK intervention are suboptimal, and we look forward to meeting this important clinical need. With the successful completion of our first cases in the US, we will introduce our product to a wider number of centers."  

About Angioslide

Founded in 2005, Angioslide is a privately held medical device company that developed a unique Embolic Capture Angioplasty solution, PROTEUS™, which provides a combination of PTA balloon and embolic suction mechanism. The PROTEUS™ device addresses an unmet need for an easy-to-use, efficient and cost-effective embolic removal solution for the peripheral vascular disease market. It is the first device of its kind to receive FDA clearance for use in lower limbs (the femoral, iliac, ilio-femoral, popliteal, tibial, peroneal, and profunda arteries). The device has also received European CE Mark approval for lower limb use and is being marketed in selected regions in Europe. Angioslide headquarters are located in Caesarea, Israel, and Denver Colorado. For more information visit our website at http://www.angioslide.com

Contact:

Shira Doron
Marketing Director
Mobile: +972-54-9011134
Email: shirad@angioslide.com


'/>"/>
SOURCE Angioslide Ltd.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Angioslide Announces FDA 510(K) Clearance of PROTEUS(TM) Below The Knee Device
2. CryoLife Announces Release Date and Teleconference Call Details for 2012 Second Quarter Financial Results
3. PTC Therapeutics Announces Achievement of Major Milestone in Wellcome Trust BMI1 Collaboration
4. Lilly Announces Pomaglumetad Methionil Did Not Meet Primary Endpoint of Clinical Study
5. Genova Diagnostics, Inc. Announces the Acquisition of Metametrix, Inc.
6. Orexigen Therapeutics Announces the Light Study is Enrolling Faster than Originally Projected
7. Shionogi-ViiV Healthcare announces positive initial data from phase III study of dolutegravir-based regimen vs Atripla in HIV
8. Elsevier Announces New Editor-In-Chief for Neurobiology of Learning and Memory
9. Express Scripts Holding Company Announces Second Quarter 2012 Earnings Conference Call
10. Inspiration Biopharmaceuticals Announces Clinical Hold of Clinical Trials Evaluating IB1001 for the Treatment and Prevention of Bleeding in Hemophilia B
11. Mesa Labs Announces New Logo
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that ... PCT (procalcitonin) assay as a dedicated testing solution for ... clearance, Roche is the first IVD company in the ... risk assessment and management. PCT is a ... in blood can aid clinicians in assessing the risk ...
(Date:6/23/2016)... Calif. , June 23, 2016 ... CST on Thursday, July 7, 2016 , , , , ... ) , , , , EXPERT PANELISTS:  , , ... Naik; Senior Industry Analyst, Christi Bird; Senior Industry Analyst, Divyaa Ravishankar ... The global pharmaceutical industry is witnessing an exceptional ...
(Date:6/23/2016)... -- The vast majority of dialysis patients currently receive ... usually 3 times a week, with treatment times averaging ... equipment preparation and wait time.  This regimen can be ... who are elderly and frail.  Many elderly dialysis patients ... for some duration of time. Residents in ...
Breaking Medicine Technology:
(Date:6/26/2016)... , ... June 26, 2016 , ... Pixel Film Studios ... X. , "Film editors can give their videos a whole new perspective by using ... - CEO of Pixel Film Studios. , ProSlice Levels contains over 30 Different ...
(Date:6/26/2016)... ... June 26, 2016 , ... Many ... been diagnosed with endometriosis. These women need a treatment plan to not only ... approach that can help for preservation of fertility and ultimately achieving a pregnancy. ...
(Date:6/25/2016)... ... ... The temporary closing of Bruton Memorial Library on June 21 due to a possible lice ... overlooked aspect of head lice: the parasite’s ability to live away from a human host, ... a necessary one in the event that lice have simply gotten out of control. , ...
(Date:6/25/2016)... ... , ... As a lifelong Southern Californian, Dr. Omkar Marathe earned his Bachelors ... Geffen School of Medicine at UCLA. He trained in Internal Medicine at Scripps Green ... hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the opportunity to train ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the ... In terms of the latter, setting the bar too high can result in disappointment, ... just slow progress toward their goal. , Research from PsychTests.com reveals ...
Breaking Medicine News(10 mins):